Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1991-3-8
|
pubmed:abstractText |
Ischemia of the lower extremity has been shown to cause pulmonary leukostasis and increased pulmonary artery pressure. Thromboxane (TX) has been implicated as a mediator in this process. The effect of OKY-046, a TX synthetase inhibitor, on polymorphonuclear leukocyte (PMN) production of superoxide anion (O2-) as determined by ferricytochrome reduction was examined. Fourteen dogs were subjected to 6 hours of bilateral gracilis muscle ischemia followed by 1 hour of reperfusion. O2- production from resting PMNs and PMNs stimulated with opsonized zymosan (OZ, 0.1 mg/ml) was measured prior to ischemia or drug treatment (baseline), and following reperfusion in both treated (n = 7) and control groups (n = 7). Serum TX levels were measured using a radioimmunoassay. Following reperfusion, TX levels in the treated group were decreased as compared with the control group (18 +/- 2 pg/ml vs. 72 +/- 26 pg/ml, P less than 0.05). Superoxide production by both resting and stimulated PMNs was also decreased in the treated group; from 0.98 +/- 0.16 nmol to 0.43 +/- 0.12 nmol O2- in the resting state (P less than 0.05) and from 13.3 +/- 1.5 nmol to 9.0 +/- 1.1 nmol O2- after stimulation (P less than 0.005). O2- production was increased in the control group following reperfusion as compared with baseline samples, and this increase was attenuated by treatment with OKY-046. TX synthetase inhibition decreases activation of PMNs following hindlimb ischemia.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Methacrylates,
http://linkedlifedata.com/resource/pubmed/chemical/Superoxides,
http://linkedlifedata.com/resource/pubmed/chemical/Thromboxane B2,
http://linkedlifedata.com/resource/pubmed/chemical/Thromboxane-A Synthase,
http://linkedlifedata.com/resource/pubmed/chemical/ozagrel
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0003-1348
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
57
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
76-9
|
pubmed:dateRevised |
2003-11-14
|
pubmed:meshHeading |
pubmed-meshheading:1847027-Animals,
pubmed-meshheading:1847027-Dogs,
pubmed-meshheading:1847027-Female,
pubmed-meshheading:1847027-Injections, Intravenous,
pubmed-meshheading:1847027-Ischemia,
pubmed-meshheading:1847027-Leg,
pubmed-meshheading:1847027-Lung Diseases,
pubmed-meshheading:1847027-Lymphocyte Activation,
pubmed-meshheading:1847027-Male,
pubmed-meshheading:1847027-Methacrylates,
pubmed-meshheading:1847027-Neutrophils,
pubmed-meshheading:1847027-Superoxides,
pubmed-meshheading:1847027-Thromboxane B2,
pubmed-meshheading:1847027-Thromboxane-A Synthase
|
pubmed:year |
1991
|
pubmed:articleTitle |
Thromboxane synthetase inhibition decreases polymorphonuclear leukocyte activation following hindlimb ischemia.
|
pubmed:affiliation |
Section of Vascular Surgery, University of Medicine and Dentistry of New Jersey, Newark 07103.
|
pubmed:publicationType |
Journal Article
|